Biosimilars Made Simple: A Micro-Analysis Of Biosimilars & Relevant Policy

With all the promise biosimilars hold, why we are not seeing increased market uptake? There are many reasons that involve policy, legislation, and the legal system that have led to the current state of the biosimilar market in the U.S. Our white paper examines the basics. We like to thank Biosimilar Development for featuring our new analysis!

Download our micro-analysis here.

Previous
Previous

Legislation to Play Significant Role in Drug Pricing Across Specialty Pharmacy

Next
Next

With the Debate Over Data Privacy Increasing, Senator Gillibrand Proposes Legislation to Create New Data Protection Agency